MAPK3 and colorectal cancer: Overall, 3c and 3d emerged as the most promising candidates, combining cytotoxic, antioxidant, HDAC inhibitory, and apoptotic effects, and may act as selective therapeutic agents by targeting the p38/MAPK-ERK1 pathway in colorectal cancer.